Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9637625 | 0.78 | NPC1 (0.56) | SMN1; SMN2KMT2A | |
| SCHEMBL4921268 | 0.74 | HDAC6 (0.69) | HDAC6HDAC1HDAC11HDAC2HDAC3 | |
| SCHEMBL4930695 | 0.74 | HDAC6 (0.53) | HDAC6HDAC1HDAC11SMN1; SMN2KMT2A | |
| SCHEMBL1566140 | 0.74 | SMN1; SMN2 (0.57) | HDAC1HDAC2SMN1; SMN2KMT2A | |
| SCHEMBL4916892 | 0.73 | KMT2A (0.49) | HDAC6SMN1; SMN2KMT2A | |
| SCHEMBL4921364 | 0.73 | HDAC1 (0.67) | HDAC6HDAC1HDAC11HDAC2HDAC3 | |
| SCHEMBL4930733 | 0.73 | HDAC6 (0.67) | HDAC6HDAC1HDAC11HDAC2HDAC3 | |
| SCHEMBL4930503 | 0.72 | SHMT2 (0.48) | HDAC6HDAC1HDAC11HDAC2HDAC3 | |
| SCHEMBL1048418 | 0.72 | NAMPT (0.63) | HDAC6HDAC3HDAC8SMN1; SMN2KMT2A | |
| SCHEMBL4916917 | 0.71 | KDR (0.47) | HDAC6HDAC8SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HDAC6 2092/4885HDAC1 563/4885HDAC11 897/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | HDAC6 2060/4885HDAC1 622/4885HDAC11 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.